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Background: Matrix metalloproteinase-2 (MMP-2) is an endopeptidase that facilitates extracellular matrix remodeling
and molecular regulation, and is implicated in tumor metastasis. Type I collagen (Col I) regulates the activation of
MMP-2 through both transcriptional and post-transcriptional means; however gaps remain in our understanding of the
involvement of collagen-binding β1 integrins in collagen-stimulated MMP-2 activation.
Methods: Three β1 integrin siRNAs were used to elucidate the involvement of β1 integrins in the Col I-induced
MMP-2 activation mechanism. β1 integrin knockdown was analyzed by quantitative RT-PCR, Western Blot and
FACS analysis. Adhesion assay and collagen gel contraction were used to test the biological effects of β1 integrin
abrogation. MMP-2 activation levels were monitored by gelatin zymography.
Results: All three β1 integrin siRNAs were efficient at β1 integrin knockdown and FACS analysis revealed
commensurate reductions of integrins α2 and α3, which are heterodimeric partners of β1, but not αV, which is not.
All three β1 integrin siRNAs inhibited adhesion and collagen gel contraction, however only the siRNA showing the
greatest magnitude of β1 knockdown inhibited Col I-induced MMP-2 activation and reduced the accompanying
upregulation of MT1-MMP, suggesting a dose response threshold effect. Re-transfection with codon-swapped β1
integrin overcame the reduction in MMP-2 activation induced by Col-1, confirming the β1 integrin target specificity.
MMP-2 activation induced by TPA or Concanavalin A (Con A) was not inhibited by β1 integrin siRNA knockdown.
Conclusion: Together, the data reveals that strong abrogation of β1 integrin is required to block MMP-2 activation
induced by Col I, which may have implications for the therapeutic targeting of β1 integrin.
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Integrins are a family of transmembrane adhesion recep-
tors that mediate cell-matrix and cell-cell interactions
[1]. β1 integrin is one of the β subunits that mechani-
cally link extracellular matrix (ECM) ligands to the cell
by triggering formation of intracellular cytoskeletal scaf-
folds that facilitate interactions between signaling pro-
teins [2]. Importantly, β1 integrin signaling has been* Correspondence: e2.thompson@qut.edu.au
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article, unless otherwise stated.shown to mediate diverse roles in cancer progression
including invasion, migration and metastasis [3-5]. The
importance of proteolytic enzymes in facilitating invasive
tumor growth has been recognized, with major contribu-
tions by matrix metalloproteinases (MMPs) [6-8].
The MMP family consists of more than 26 endopepti-
dases and has a clear connection to ECM degradation and
cancer cell invasion. It is increasingly implicated in the
proteolysis of important cell regulatory molecules, includ-
ing cytokines and growth factors, and their receptors and/
or inhibitors [9]. Although several MMPs have been asso-
ciated with tumor progression, particular attention has
been focused on MMP-2 and membrane type-1 MMPentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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substrates including ECM (e.g. collagens, fibronectin,
laminins) and non-ECM molecules, and is a potent
modifier of the tissue microenvironment. Its expression
is closely associated with tumour growth and invasion in
animal models, and cancer progression in patients [12-14].
Activation of pro-MMP-2 proceeds on the cell surface
and is mediated by a tri-molecular complex of MT1-MMP,
TIMP-2 and MMP-2 [15,16]. Collagen type I (Col I) has
been shown to stimulate MT1-MMP-mediated MMP-2-
activation in several cell types [17-22]. Col I can cause acti-
vation of MMP-2 through increasing MT1-MMP mRNA
and protein levels (transcriptional response). However, an
alternate pathway has been observed in which Col I in-
creases the activity of pre-existing MT1-MMP molecules in
order to activate MMP-2 [23]. We previously demonstrated
that Col I induces MT1-MMP-mediated MMP-2 activation
by blocking MT1-MMP internalization, thereby stimulating
MMP-2 activation [24]. However, previous studies have
indicated that cellular interaction with Col I is mediated
largely through integrin α1β1, α2β1 and α3β1 receptors
[25-27], and cross linking of integrin β1 could activate
MMP-2 in ovarian carcinoma cells, suggesting direct in-
volvement of integrin signaling in MMP-2 activation [21,28].
Involvement of integrin β1 activation has been de-
monstrated in MT1-MMP effects on skeletal stem cell
commitment [29], and Mori et al. have implicated the
transmembrane/cytoplasmic domains of MT1-MMP in
mammary branching morphogenesis via direct binding
to integrin β1 [30]. Despite this clear implication of β1
integrin in MT1-MMP functionality, the involvement
of β1 integrin in MMP-2 activation in response to Col I
stimulation is still not precisely understood, with a recent
study suggesting a direct interaction between MT1-MMP
and Col I leading to MT1-MMP stabilization in an
integrin-independent manner [31]. Our study further in-
vestigated β1 integrin involvement in MMP-2 activation
in response to Col I stimulation in breast cancer cells, and
found it played an important role in this process.Materials and methods
Plasmids, siRNA, antibodies and reagents
MCF-7-MT1 cells: Stable transfection of MT1-MMP
into MCF-7 cells previously transfected with β-galactosidase
was previously described [32,33]. The pcDNA-β1 vector
was constructed by cloning human β1 integrin cDNA into
pcDNA3.1. A codon-swapped mutant form of the human
β1 integrin (β1-Mt) was generated by the QuickChange
site-directed mutagenesis kit (Invitrogen, Melbourne,
Australia). Two synthetic oligonucleotide primers were
designed to generate 7 point mutations in the β1/6 integrin
siRNA recognition site: TGCTGATATGGAAACTACTTA
TGATTATACACGACAGAAGGGAGTand ACTCCCTTCTGTCGTGTAT AATCATAAGTAGTTTCCATATCA
GCA.
Three β1-integrin siRNAs (Pro-Oligo, Australia)
were found active for β1 integrin knockdown: β1-integrin
siRNA#4 (β1/4), AATTAGCATAACTTCAAATAA, β1-
integrin siRNA#5 (β1/5), AATGGCTTAATTTGTGG
AGGA, and β1-integrin siRNA#6 (β1/6), AAGCTTT
TAATG ATAATTCAT.
Antibodies against the following proteins were pur-
chased from Chemicon (Boronia, Australia): integrin β1
(AB2510), αV (L320), α1 (MAB19732) α3 (MAB19522)
and MT1-MMP (AB815). Antibody toward α2 integrin
(Ak7) was a kind gift from Dr. Michael Berndt (Monash
University, Melbourne) and a pan-actin antibody was
from Biosource (Camarillo, CA). Con A, TPA (12-O-tet-
radecanoylphorbol-13-acetate), vitronectin (VN), fibro-
nectin (FN) and laminin-1 (LM) were from Sigma
(Castle Hill, Australia). Recombinant full-length pro-
MMP-2 expressed in a vaccinia virus system (rMMP-2)
was a kind gift from Dr. Rafael Fridman (Wayne State
University, Detroit, MI). Col I (Vitrogen 100) was ob-
tained from Cohesion (Palo Alto, CA). Alexa Fluor 568-
conjugated goat anti-mouse secondary antibody and
Alexa Fluor 488-conjugated donkey anti-rabbit second-
ary antibody were obtained from Molecular Probes
(Eugene, OR).
Cell culture and transfection
MCF-7-MT1 and MDA-MB-231 cells were maintained
in Dulbecco’s Modified Eagle’s Medium (DMEM; Life
Technologies, Auckland, New Zealand) with 10% fetal
bovine serum (FBS; JRH Biosciences, Lenexa, KS).
SiRNA transfections were performed using Lipofecta-
mine™ 2000 (Invitrogen, Life Technologies). Plasmid
transfections were performed using Fugene6 reagent
(Roche, Mannheim, Germany) with 2 μg of plasmid
DNA. For co-transfection of human β1 integrin and β1
integrin siRNAs, MCF-7-MT1 and MDA-MB-231 cells
were transfected with β1/6-integrin siRNA using Lipo-
fectamine™ 2000 as described above. The siRNA-
transfected cells were subsequently transfected with
either wild-type or mutant β1 integrin as indicated using
Fugene6 with 2 μg plasmid DNA. Recombinant full-
length pro-MMP-2 was added at 100 ng/ml. At the ap-
propriate time point, the conditioned media and cell
lysates were collected.
DNA synthesis and quantitative PCR
cDNA was prepared from 100 ng of total RNA isolated
with the Qiagen RNeasy mini-column kit (Qiagen,
GmbH, Germany) using Superscript II reverse tran-
scriptase (Invitrogen) and random primers. Human ribo-
somal protein L32 mRNA was used as a housekeeping
gene for normalization [34]. qRT-PCR was performed on
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Elmer Applied Biosystems, Australia) with cDNA gener-
ated from an equivalent of 2 ng of RNA as previously
described [24]. The primer sequences used were for L32:
CAGGGTTCGTAGAAGATTCAAGGG and CTTGGA
GGAAACATTGTGAGCGATC; α1 integrin: GCTGAC
CAGTCAGCAGCTTCATTT and CTCCAGAAGAAG
CAGTAGCAGAGTTT; α2 integrin: GACCTATCCAC
TGCCACATGTGAAAAA and CCACAGAGGACCA
CATGTGAGAAAA; α3 integrin: CGCAGGTGGGCGC
CTATTTT and GGCACCCCCTACTTCCTCTTT; αV
integrin: GGCAGTGC CATAGCTCCTTT and CCCA
CTGCCCTTCAAGGGATTT; β1 integrin: GACTGAT
CAGTTCAGTTTGCTGT GTGTTT and CCCTGCTT
GTATACATTCTCCACATGATTT. Reaction conditions
were 95°C for 10 minutes followed by 50 cycles of 95°C
for 15 s and 60°C for 1 minute. The difference in average
cycle threshold (dCT) between L32 (housekeeping) and
the gene of interest was determined from quadruplicate
readings for each sample.
Flow cytometry
Cells were trypsinised and resuspended in FACS buffer
(2% FCS in PBS, 0.02% sodium azide) at 1×106 cells/ml,
then incubated with 10 μg/ml antibodies to integrins α1,
α2, α3, αV, and β1. Cells were then washed and incu-
bated with FITC-conjugated goat anti-mouse or swine
anti-rabbit IgG (Dako) and analyzed on a FACScan cyt-
ometer (Becton-Dickinson, Mountain View, CA).
Immunofluorescence
Cells were plated on teflon printed glass slides (Electron
Microscopy Sciences, Ft. Washington PA) and fixed with
3% paraformaldehyde/PBS then blocked with 5% BSA/
0.25% Triton X-100. Cells were then washed in PBS and
incubated with primary antibodies toward β1 integrin
(AB2511) or MT1-MMP (AB815). Cells were washed
and probed with a donkey anti-rabbit Alexa Fluor 488-
conjugated antibody for β1 integrin or an Alexa Fluor
568 secondary antibody for MT1-MMP. Nuclei were
then stained with propidium iodide (0.25 mg/ml), then
the cells were washed and mounted using fluorescent
mounting medium (Dako) and viewed by confocal mi-
croscopy (BioRad MRC 1024, Hemel Hempstead, UK).
Cell lysates and Western blot
Cells were lysed with 10 mM Tris–HCl pH 7.6, 10 mM
NaCl, 3 mM MgCl2 and 1% Nonidet P-40 containing
Protease Inhibitors (Roche), then cleared by centrifuga-
tion at 6,000 rpm for 10 minutes. Protein concentrations
were determined with a BCA protein quantification
assay (Pierce, Rockford IL). Equal amounts of lysates were
electrophoresed with 10% SDS-PAGE under reducing
conditions (100 mM DTT, Sigma). After electrophoresis,proteins were transferred to PVDF membranes and
blocked with 5% skim milk. Blots were incubated with
primary antibodies overnight and then probed with an
HRP-conjugated secondary antibody (Pierce). Detection
was performed using the ECL + Plus system (Pierce).Conditioned medium isolation and gelatin zymography
Cells were plated for near confluence at 37°C overnight.
After each treatment, cells were washed twice with
serum-free medium (SFM: unsupplemented DMEM),
then replaced with fresh SFM. Recombinant full-length
pro-MMP-2 (kindly, provided by Dr. Rafael Fridman,
Wayne State University, Detroit, MI, USA) was added at
100 ng/ml concentration. At the appropriate time point,
the conditioned medium was collected, transferred to a
microcentrifuge tube and centrifuged at 6000 rpm for
10 minutes at 4°C. MMP-2 activation was analyzed by
gelatin zymography using 5% polyacrylamide stacking
gel and 10% polyacrylamide resolving gel (Bio-Rad Co.,
Richmond, VA) containing 1 mg/ml gelatin (BDH
Laboratory Supplies, Poole, UK). Equal amounts of con-
ditioned media were mixed with SDS sample buffer
under non-reducing conditions. After electrophoresis,
gels were washed with 50 mM Tris–HCl pH 7.5, 5 mM
CaCl2 and 2.5% Triton X-100 and then incubated in
50 mM Tris–HCl pH 7.5, 5 mM CaCl2 at 37°C over-
night. Gels were stained with 0.25% Coomassie Brilliant
Blue (R-250) dye in 10% acetic acid and 10% isopropa-
nol. Semiquantitative densitometry was performed using
the Image J 1.46 program (NIH). Data is expressed as
percent of area.Collagen gel contraction assay
Collagen gels were made from Col I (Vitrogen 100, 3
mg/ml), neutralized with 1 M sodium hydroxide, pH 8.0
and then diluted in PBS to a final concentration of 2
mg/ml of Col I in 10 mM of sodium hydroxide. Cells
were resuspended such that one part of the cell suspen-
sion was mixed with nine parts of the collagen solution,
to give a final concentration of 4×105 cell/ml. A total of
500 μl of cell-collagen mixture was added to 24 well
plates and gels were allowed to polymerize for 60 min at
37°C. In order to release the gels, a yellow tip was
inserted around and underneath the gels. The relaxed,
floating gels were immersed with 1 ml medium and
incubated at 37°C. The gel diameters were measured
daily for 5 days using an inverted microscope. Collagen
gel contraction is indicated as the decrease in gel area
expressed as a percentage. Each experiment was per-
formed in triplicate and with 3 independent experi-
ments. Statistical analysis was performed by Student’s
t-test.
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Col I, fibronectin and vitronectin (0.5 ug/ml, 100 uL/well)
were coated on 96-well plates at 37°C for 60 minutes and
the wells were then washed and blocked in 3% BSA. Cells
were detached from culture by Versene, resuspended at
2.5× 105 cells/ml, and incubated at 37°C for 60 minutes to
allow recovery of cell surface proteins. Cells (100 μl; 2.5×
104 cells) were added to the wells and incubated at 37°C
for 60 minutes. The adherent cells were stained with 0.5%
Crystal Violet in 25% methanol for 5 minutes. Wells were
then washed, dried and solubilization of the Crystal Violet
was performed with 0.1 M sodium citrate containing 50%
ethanol. Absorbance was measured at 540 nm (Power
Wave X, Bio-Tek Instruments, Inc., Winooski, VT). Each
experiment was performed in triplicate and 3 independent
experiments were performed. Student’s t-test was used for
statistical analysis.
Results
Knockdown of β1 integrin expression by siRNAs
β1 siRNAs β1/4, β1/5 and β1/6 were effective in knocking-
down β1 integrin expression, however, β1/6 siRNA was
more efficient than β1/4 and β1/5 in MCF-7-MT1
(Figure 1A) and MDA-MB-231 cells (data not shown). We
hypothesized that β1 integrin knockdown would also affect
the cell surface expression of the α subunit heterodimer
partners. Integrin α1β1, α2β1, α10β1 and α11β1 are the
major collagen-binding integrin receptors [35,36]. MCF-7-
MT1 cells had very low levels of α1, and no detectable
levels of α10 or α11 integrin mRNA (data not shown).
FACS analysis for α2, α3, and αV integrins showed that all
three siRNAs also caused reduced cell surface levels of α2
and α3 integrin subunits. MCF-7-MT1 cells had low levels
αV integrin, and no effect of the β1 siRNAs on αV integrin
levels was observed (Figure 1B).
β1/6 siRNA demonstrated the most effective abrogation
of β1 integrin biological function
β1 integrin can bind multiple additional partners to form
integrins in addition to the primary Col I receptors
α1β1, α2β1, α10β1 and α11β1 [35,36]. Integrins α3β1,
α6β1, α6β4 and α7β1 are major LM receptors [37].
Integrins α5β1 and α8β1 are major FN receptors. Integ-
rin αIIbβ3 is an alternate FN receptor, while αvβ3 is spe-
cific for VN [36]. To examine the functional effects of
inhibiting integrin β1 expression, adhesion analysis was
performed with ECM substrates including VN, FN, and
Col I after β1 integrin siRNA transfection. β1/6 integrin
siRNA-treated cells showed significantly less adhesion
(p < 0.05) to Col I (Figure 2A). Decreased adhesion to
FN was observed for β1/4, β1/5 and β1/6 siRNAs com-
pared to the control siRNA cells (p < 0.05, 0.05 and 0.01
respectively), and again β1/6 integrin siRNA showed a
stronger effect than β1/4 and β1/5 (data not shown).None of the β1 siRNA treated cells showed any reduc-
tion in adhesion to VN (ligand for αvβ3), confirming
that the β1 effects were specific (data not shown).
Collagen gel contraction was clearly observed with
MDA-MB-231 cells and partial contraction was seen
with MCF-7-MT1 cells. Collagen gel contraction ap-
peared completely inhibited by β1/6 siRNA compared to
β1/4 and β1/5 at Days 1, 3 and 5 in MDA-MB-231 cells
(Figure 2C). All of the β1 integrin siRNA treated cells
showed less collagen contraction than the siRNA control
at Day 5 (Figure 2C). However, only β1/6 siRNA-treated
cells showed significantly (p < 0.01) reduced ability to
initiate collagen gel contraction on the first and all sub-
sequent days (Figure 2D), while β1/4 and β1/5 integrin
siRNAs initially failed contraction on the first day, but
resumed contraction on the second and subsequent
days. Consistent with the above results, only β1/6 integ-
rin siRNA caused a significant reduction in collagen gel
contraction (16.9%, p <0.001) compared to β1/4 and β1/5
(Figure 2D).Abrogation of β1 integrin expression suppressed Col I-
induced MMP-2 activation via MT1-MMP up-regulation
In MCF-7-MT1 cells, Col I caused activation of MMP-
2 despite MT1-MMP being under the control of a
heterologous promoter. Furthermore, when these cells
were treated with cycloheximide to block new protein
synthesis, some reduction in MMP-2 activation was
seen, but the MMP-2 activational response to Col I was
still observed [32]. Thus, MCF-7-MT1 cells provide an
ideal model for studying non-transcriptional regulation
of Col I-induced MMP-2 activation. Again, integrin ex-
pression appeared completely abrogated by β1/6 siRNA
compared to β1/4 and β1/5 at 72, 96 and 120 hours in
MCF-MT1 cells (Figure 3A). All three β1 integrin siR-
NAs caused reduced MMP-2 activation. Both β1/4 and
β1/5 integrin siRNAs reduced Col I-induced MMP-2
activation at 24 hours and showed sustained reduction
until 48 hours after knockdown, after which Col
I-induced MMP-2 activation was not evident (i.e. be-
tween 72 and 120 hours after knockdown). On the
other hand, reduced MMP-2 activation with β1/6 integ-
rin siRNA was seen at 72 hours after knockdown, and
continued to decrease, again showing that β1/6 was
more efficient than β1/4 and β1/5 in both MCF-7-MT1
(Figure 3B) and MDA-MB 231 cells (data not shown)
Col I-stimulated MMP-2 activation functions princi-
pally via MT1-MMP in fibroblasts, as no MMP-2 activa-
tion occurs in MT1-MMP-deficient mouse fibroblasts in
response to Col I [38,39]. Since we found that abroga-
tion of β1 integrin expression was able to suppress Col
I-stimulated MMP-2 activation, the influence of β1 integ-
rin on MT1-MMP activity was examined. Interestingly,
AB
Figure 1 Knockdown of β1 integrin expression by β1 siRNA in MCF-7-MT1 cells. Integrin β1 and control siRNAs were transfected into
MCF-7-MT1 cells. (A): RNA was collected after 24 hours transfection and analyzed for β1 integrin expression by qRT-PCR. (B): 72 hours after
transfection, cells were analyzed by flow cytometry for α2, α3, αV and β1 integrin. Control panel depicts cells stained with secondary
antibody alone.
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creased MT1-MMP levels, however, the β1/6 integrin
siRNA showed the strongest decrease, which correspondedto the lowest β1 integrin level compared to controls
(siRNA control) (Figure 3C and D) and the highest sup-
pression of MMP-2 activation.
A B
C D
Figure 2 Reduced functional activity in β1 integrin knockdown cells: (A): Adhesion assay of β1 integrin knockdown MCF-7-MT1 cells
for Col I. (B): MDA-MB-231 cells were transfected with the indicated siRNAs. At appropriate time points, cell lysates were collected for analysis of
β1 integrin levels by Western blot. (C): Collagen gel contraction by MDA-MB-231 cells after transfection with β1/4, β1/5, β1/6 and control siRNAs.
24 hours after transfection, collagen gels were made at 2 mg/ml and the cells resuspended to a final concentration of 4 × 105 cell/ml. Gels were
polymerized and then the gels were released. The relaxed, floating gels were immersed in 1 ml medium with 10% FCS. The gel diameters were
measured daily for 5 days. Collagen gel contractions were calculated as mean values in relation to the gel diameters before releasing, as shown
in (D). Collagen gel contractions were performed in triplicate independently and mean percent of collagen gel contraction was compared using
Student’s t-test.
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tigated by immunofluorescence. β1 integrin expressing cells
were better spread, whereas all β1/5 and β1/5 knockdown
cells displayed rounder and less-spread morphology, with
β1/6 integrin siRNA being most pronounced (Figure 3E).
Cell surface β1 integrin localized to the cell periphery while
MT1-MMP was more diffusely distributed across the cell
but concentrated on the cell surface, and the levels of
MT1-MMP appeared to correlate with those of β1 integrin.
Reduced cell surface β1 integrin and MT1-MMP was only
seen for β1/6 integrin siRNA–treated cells, compared to
β1/4 and β1/5, irrespective of Col I treatment (Figure 3F).
Additionally, β1 integrin and MT1-MMP levels examined
by immunofluorescence corresponded to Western blot de-
termination (Figure 3C, D). Thus, β1/6 integrin siRNA
showed the most efficient β1 integrin knockdown, which
coincided with the strongest reduction of MT1-MMP.To confirm that the reduced MMP-2 activation after
β1 integrin knockdown was due to reduced MT1-MMP,
MCF-7-MT1 cells were transfected with β1/4, β1/5 and
β1/6 integrin siRNAs, and subsequently transfected with
MT1-MMP. Forced MT1-MMP expression was con-
firmed (Figure 3G), and the expected suppression of Col
I-induced MMP-2 activation by β1/6 integrin siRNA
treatment was rescued (Figure 3H). These results con-
firm a role for β1 integrin in regulating MT1-MMP to fa-
cilitate MMP-2 activation in response to Col I stimulation.
High threshold of β1 Integrin knockdown required to
inhibit MMP-2 activation in response to Col I stimulation
There are several factors that may influence the effi-
ciency of RNAi in mammalian systems including the
choice of the target site of degradation, the transfection
method and the turnover rate of the protein. In addition,
Figure 3 (See legend on next page.)
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Figure 3 Time course of β1 integrin knockdown and MMP-2 activation in MCF-7-MT1 cells. (A): MCF-7-MT1 cells were transfected with the
indicated siRNAs. At the indicated time points, cell lysates were collected for analysis of β1 integrin levels by Western blot. (B): Zymogram: MCF-7 cells were
transfected with the indicated siRNAs. rMMP-2 was added at serial time points after β1 integrin siRNA transfection and cells were treated where indicated
with Col I. Conditioned medium was collected and MMP-2 activation was assessed by zymography. Semiquantitative densitometry was performed and is
expressed as percent area. (C): MT1-MMP levels were reduced in β1 integrin - abrogated cells. MCF-7-MT1 cells were transfected with the indicated siRNAs,
and protein levels of β1 integrin and MT1-MMP were examined by Western blot at 72 hours after transfection. (D): MT1-MMP densitometry was analyzed
and is expressed in arbitrary units. (E): The indicated siRNAs were transfected into MCF-7-MT1 cells, incubated for 6 hours cells were then mounted and
viewed by light microscopy. (F): Immunofluorescence analysis for β1 integrin and MT1-MMP at the MCF-7-MT1 cell surface. After 72 hours transfection,
cells were plated on Teflon printed glass slides and treated with Col I where indicated. Cells were subjected to immunofluorescence and then viewed
by confocal microscopy. (G): Ectopic MT1-MMP expression rescued suppression of Col I-induced MMP-2 activation by β1/6 integrin siRNA. MCF-7-MT1
cells were transfected with the indicated siRNAs, and subsequently transfected with MT1-MMP. Cells were then left untreated or treated with Col I.
Efficiency of MT1-MMP inductions were determined by Western Blot. (H): MMP-2 activation was analyzed by zymography. Semi-quantitative
densitometry is expressed in percent of area.
Figure 4 Dose response effect of β1 integrin siRNA on MMP-2 activation in MCF-7-MT1 cells. (A): Cells were plated and transfected with
β1 integrin siRNA. Serial dilutions of β1/6 siRNA (2.5, 5, 10, 15 and 20 μM) were used in comparison with the 20 μM concentrations of β1/4 and
β1/5 siRNAs. Protein concentrations were determined and equal amounts of lysates were electrophoresed with 10% SDS-PAGE under reducing
conditions. Western Blot analysis was used to detect β1 integrin and MT1-MMP levels (B). (C): Serial dilutions of β1/6 siRNA (5, 10, and 20 μM)
were used in comparison with the 20 μM concentrations of β1/4 and β1/5 siRNAs. Conditioned medium was collected and effects on MMP-2
activation were examined by zymography.
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Figure 5 The target site of β1/6 integrin siRNA was specific to β1 integrin gene. Site-specific mutagenesis primers were designed around
the target site of the β1/6 siRNA. Co-transfections of β1/6 siRNA and either wild type β1 integrin or β1 integrin codon-swapped mutant were performed.
(A): Western blot analysis of β1 integrin and MT1-MMP expressions, and the effects on MMP-2 activation were examined by zymography in MCF-7-MT1
cells (B). (C): MCF-7-MT1 cells were treated with Col I (100 μg/ml), Con A (10 μg/ml) or TPA (100nM) after β1/6 siRNA transfection. Conditioned medium
was collected and effects on MMP-2 activation were examined by zymography. Semi-quantitative densitometry was performed using the Image J 1.46
program (NIH) and is expressed in percent of area.
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encing target gene knockdown by siRNA technology
[40,41]. This effect is dependent on the dose response to
siRNA concentration. We examined whether β1/4, β1/5
and β1/6 siRNAs had dose-dependent effects on theabrogation of β1 integrin mRNA expression, and
whether this was relative to the reduction seen in MMP-
2 activation. We hypothesized that the β1/6 siRNA
showed a quicker mRNA degradation rate than either
β1/4 or β1/5 siRNA. Serial concentrations of β1/6 siRNA
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that at the lowest concentration (2.5 μM), β1/6 siRNA
was able to knockdown β1 integrin expression to an ex-
tent comparable to the highest concentration (20 μM) of
β1/4 or β1/5 siRNA (Figure 4A). The β1 integrin expres-
sion was below the threshold of detection 72 hours after
transfection with 2.5 and 5 μM of β1/6 siRNA, and this
was also seen with β1/4 and β1/5 siRNA at 20 μM.
MMP-2 activation reductions were observed only at 20
μM of β1/6 integrin siRNA (Figure 4C), was which rela-
tive to reduction of MT1-MMP protein level at this con-
centration (Figure 4B). These results indicate that the
reduction of Col I-induced MMP-2 activation seen only
with β1/6 may require the more rapid and complete
knock down of β1 integrin seen with this siRNA. A
threshold of β1 integrin knockdown that cannot be sur-
passed by β1/4 or β1/5 siRNAs may exist for the MMP-
2 activation effect.
The suppression of MMP-2 activation by β1/6 siRNA was
specific to β1 integrin
Wild-type β1 integrin transfection was successful at in-
creasing β1 integrin expression at all time points, however,
strong inductions were observed at 12 and 24 hours after
transfection. Consistently, cells over-expressing β1 integrin
showed higher MT1-MMP expression than vector control
cells at 24, 48 and 72 hours (Figure 5A). The MT1-MMP
levels in the vector control cells resembled that seen in β1
integrin knockdown cells without any further transfection
(Figure 3C).
Co-transfection of β1 integrin codon-swapped mutant
and β1/6 integrin siRNA failed to knockdown β1 integ-
rin, whereas co-transfection of wild-type β1 integrin and
β1/6 integrin siRNA (β1/6 integrin siRNA alone) suc-
cessfully knocked down β1 integrin (Figure 5A). Co-
transfection of β1 integrin codon-swapped mutant and
β1/6 integrin siRNA rescued the otherwise inhibited
MMP-2 activation in both MCF-7-MT1 cells (Figure 5B)
and MDA-MB-231 cells (data not shown). These results
indicated that the stronger effect of β1/6 integrin siRNA
was specific to β1 integrin.
Stimulators of MMP-2 activation that do not function
through β1 integrins, such as Con A and TPA, would be
expected to remain unaffected by β1 integrin knock-
down. As expected, MMP-2 activation by Con A or TPA
was not inhibited by β1/6 integrin siRNA treatment
(Figure 5C).
Discussion
The β1-integrins have been linked to tumor progression
and the remodeling of extracellular matrix (ECM) asso-
ciated with this progression [42,43]. Collagen is a major
ECM component that plays an important role in main-
taining tissue architecture. Several studies point to thenecessity of matrix degradation for migration and inva-
sion through interstitial collagen by normal and neoplas-
tic cells, consistent with observations that fibrillar Col I
stimulates activation of MMP-2 [17,18,21,22,24,31,44].
Several studies have shown that culturing cells within a
gel of Col I stimulates MMP-2 activation through both
transcriptional and non-transcriptional enhancement of
MT1-MMP [17,18,22,23], and indicated that collagen-
binding integrins interact with collagen for this mechan-
ism [19,28,31]. Clustering of integrin β1 was shown to
cause increased cell surface MT1-MMP, colocalization
of MT1-MMP with integrin, and increased MMP-2 acti-
vation [21,28]. In contrast, a recent study indicated that
inhibition by integrin β1-targeting siRNA did not affect
3-D collagen-induced cell surface localization of MT1-
MMP or MMP-2 activation in mesothelioma cells [31].
These authors concluded that 3-D collagen scaffolding
provides a direct and multivalent interaction with MT1-
MMP, allowing MMP-2 activation to occur in a cell
surface MT1-MMP-dependent manner, rather than a
manner regulated by matrix stiffness and integrin β1
function. Our results are inconsistent with these studies,
showing an important role of integrin β1 in both the
stabilization of MT1-MMP protein levels by collagen,
and the increased activation of MMP-2.
In the transcriptional response of Col I-induced
MMP-2 activation, Col I can increase MT1-MMP
mRNA and protein levels, thereby promoting MMP-2
activation. MCF-7-MT1 is a breast cancer cell line that
lacks endogenous MT1-MMP expression. In MCF-7-
MT1 cells, which are stably transfected with MT1-MMP,
Col I causes activation of MMP-2 despite MT1-MMP
being under the control of a heterologous promoter.
Furthermore, when these cells were treated with cyclo-
heximide to block new protein synthesis, some reduction
in MMP-2 activation was seen, but the Col I response was
still observed. Thus, MCF-7-MT1cells provide a model for
non-transcriptional regulation of Col I-induced MMP-2
activation [24]. In the non-transcriptional response, Col I
blocks MT1-MMP internalization, causing retention of
MT1-MMP on the cell surface, and leading to increased
MMP-2 activation [24]. Interestingly, the engagement and
clustering of β1 integrins on endothelial cells by Col I has
been shown to induce a physical interaction between
MT1-MMP and β1 integrin, which correlated with an in-
hibition of MT1-MMP internalization [43]. Moreover, β1
integrins are mainly associated with the 60-kD mature
form of MT1-MMP, pointing to an association with active
MT1-MMP [43]. Treatment with anti-β1 integrin neutral-
izing antibodies caused impaired MT1-MMP localization
at cell–cell contacts, suggesting that the β1 integrin inter-
action might be important for MT1-MMP localization.
Col I did not alter total MT1-MMP protein levels, nor
did it directly induce MT1-MMP oligomerization. Col I
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cell periphery compared to unstimulated cells that dis-
played a more diffuse staining pattern. In addition, Col I
blocked the internalization of MT1-MMP in a dynamin-
dependent manner via clathrin-coated pit mediated
endocytosis [24]. In the current study, we found that
abrogation of β1 integrin blocked up-regulation of MT1-
MMP activity by Col I; β1 integrin knockdown reduced
overall MT1-MMP protein levels. These findings sup-
port previous observations that a physical interaction
between MT1-MMP and β1 integrin correlates with an
inhibition of MT1-MMP internalization in the presence
of Col I [45].
MMP-2 activation and fibrillar collagen degradation
are thought to be important functions of MT1-MMP.
Both of these activities uniquely require MT1-MMP
to be in a dimeric form on the cell surface, and inhib-
ition of dimerisation effectively inhibits these activities
[46,47]. The β1/6 integrin siRNA not only caused the
most efficient knockdown of β1 integrin, but also most
highly affected down-regulation of MT1-MMP. This
reduction of MT1-MMP in response to Col I in β1/6
integrin siRNA knockdown cells was neutralized by
MT1-MMP overexpression, which caused a reciprocal
strong induction of β1 integrin at 12 and 24 hours, simi-
lar to the time frame in which the transiently transfected
MT1-MMP expression takes place (data not shown).
This subsequently enhanced the Col I-induced MMP-2
activation by MT1-MMP. These data complement previ-
ous studies indicating that down-regulation of β1 integ-
rin reduces expression of MT1-MMP [48]. In addition,
MT1-MMP cooperates with β1-integrin during the mi-
gration of endothelial cells on various ECMs [16], and
was found to colocalize with β1-integrin in actin-rich,
“collagenolysis-free” leading edges of migrating fibro-
sarcoma and breast carcinoma cells grown on a 3D col-
lagen matrix [49]. In our system, the suppression of
MMP-2 activation by β1/6 integrin siRNA was specific
to Col I stimulation, and did not affect MMP-2 acti-
vation stimulated by Con A or TPA. Con A likely works
by clustering proteins with terminal sialic acid residues,
however it seems not to include β1 integrin [50].
Although we identified that abrogation of β1 integrin
caused reduced Col I-induced MMP-2 activation, we
observed that a very high threshold of inhibition was re-
quired, more so than needed for other β1 integrin func-
tionalities such as substrate adhesion and collagen gel
contraction. Collagen gel contraction occurs through a
process of reorganization of the collagen fibrils, and is
used as an in vitro model of cell-mediated tissue remod-
eling, including wound contraction and maintenance of
tissue homeostasis [51]. Several studies have demon-
strated a role for β1 integrins, in particular α1β1 and
α2β1 integrins, in mediating collagen gel contraction byfibroblasts and osteoblasts [52,53]. The three β1 integrin
siRNAs tested showed good knockdown of β1 integrin,
but only β1/6 caused a reduction in Col I-stimulated
MMP-2 activation. β1 integrin siRNAs showed knock-
down of β1 integrin expression after 24 hours of trans-
fection, however, complete knockdown of β1 integrin
was only observed at 72 hours. Importantly, the reduc-
tion in MMP-2 activation occurred at 72 hours, com-
mensurate with the most complete abrogation of β1
integrin. The only β1 integrin siRNA that blocked Col I-
induced MMP-2-activation was more potent in terms of
both dose response and time course of inhibition than
the other 2 tested, suggesting that an important thresh-
old may exist for the level of β1 integrin required to me-
diate Col I-stimulated MMP-2-activation. It is possible
that the mesothelioma study [29] did not achieve suffi-
cient abrogation of β1 integrin to reduce MMP-2 activa-
tion at 48 hours after transfection integrin β1-targeting
siRNA where β1 integrin is not complete knockdown.
MT1-MMP expression is induced in fibroblast and
endothelial cells by culture in three-dimensional collagen
matrixes [19,23]. Therefore, signaling pathways initiated
through collagen binding β1 integrin may regulate MT1-
MMP expression. The interaction between β1 integrin
and MT1-MMP blocks MT1-MMP internalization and
causes increased MMP-2 activation. It is now widely ac-
cepted that MT1-MMP is regulated by and/or associated
with integrin/FAK/Src/P13C as a pathway to promote
pericellular proteolysis and invasion in 3-dimensional
cultures [54], in part due to focal adhesion turnover
[55,56]. FAK-mediated src phosphorylation of endophilin
A2 inhibits endocytosis of MT1-MMP and promotes
ECM degradation [57]. In addition, osteopontin, an
ECM protein, is able to interact with αVβ3 integrin to
enhance MT1-MMP expression, stimulate MMP-2 acti-
vation, and induce cell migration and invasion in murine
melanoma cells [58]. Several lines of evidence suggest
that integrin αVβ3 binds MMP-2 and acts as a receptor
for surface-localized MMP activity. These studies dem-
onstrated that αVβ3 and MMP-2 were co-localized on
the surface of invasive angiogenic vascular cells, and
melanoma or cervical cancer cells [16,59,60]. In our
MCF-7-MT1 or MDA-MB-231 cells, overexpression of
β1 integrin did not stimulate MMP-2 activation despite
an apparent increase in the steady state levels of total
MT1-MMP. These observations support a complex
biphasic model whereby Col I-ligated β1-integrin acts
both locally and via signaling to upregulate pericellular
proteolysis.
Conclusions
This study confirmed the role of β1 integrin in the
MMP-2 activation response of breast cancer cells to Col
I. This work has demonstrated that abrogation of β1
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α3 integrins, and reduced MMP-2 activation in response
to Col I. The reduction in MMP-2 activation required
the most complete abrogation of β1 integrin, suggesting
that an important threshold may exist for the level of β1
integrin required to mediate Col I-stimulated MMP-2-
activation. This may provide insights into the mechan-
ism involved in the reciprocal regulation of integrin and
MMPs on the surface of tumour cells.
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